Company Overview and News

10
HSBC plans wealth hiring spree in CEO's bet on Asia's rich

16h theedgemarkets
(Sept 18): HSBC Holdings Plc is planning to increase its wealth-management staff in Asia, as Chief Executive Officer John Flint bets on growth in the region.
DGLD HSNGF CS 0011 HSB D05 UGLD HSNGY UBS DBSDF HSBC HBCYF DBSDY DSLV C VIIX BHKLY CSSLF VIIZ 2388 HCS 0005 CSGKF CGBBW BNKHF HSEA HSEB ZIV USLV TVIX ULSGF XIV

 
China commerce minister says U.S. unilateralism, protectionism will hurt global economy

19h reuters
BEIJING, Sept 18 (Reuters) - China’s commerce minister told representatives of foreign firms on Monday that the United States’ unilateralism and protectionism will impact both U.S. and China’s interests and hurt the global economy.
TM BC94 TYT SMSN TOYOF HCS HSB 0005 7203 HSEA HSEB HSBC HBCYF SMSD

 
China commerce minister says U.S. unilateralism, protectionism will hurt global economy

19h reuters
BEIJING (Reuters) - China’s commerce minister told representatives of foreign firms on Monday that the United States’ unilateralism and protectionism will impact both U.S. and China’s interests and hurt the global economy.
TM BC94 TYT SMSN TOYOF HCS HSB 0005 7203 HSEA HSEB HSBC HBCYF SMSD

 
Tale of Two Oil Markets: Brent Bulls Split From US Optimists

2018-09-17 rigzone
(Bloomberg) -- For oil investors, this is both the best of times and the worst of times, depending on which crude benchmark you trade.
HSB 0005 HSEA HSEB HCS HSBC HBCYF

2
UBS Group Choses Frankfurt as Operations Hub Post Brexit

2018-09-17 zacks
UBS Group AG (UBS - Free Report) has selected Germany’s financial hub Frankfurt over London as its new base for post-Brexit operations, per Bloomberg. Additionally, UBS plans to open offices in Madrid, Paris and Milan as part of its multi-location strategy in the European Union.
DB HCS HSB 0005 UBS HSEA HSEB HSBC ULSGF HBCYF

45
Deutsche (DB) to Shift Large Portion of Assets From London

2018-09-17 zacks
Deutsche Bank (DB - Free Report) is planning to transfer a large chunk of assets from its London base to Frankfurt headquarters post Brexit, per an article by Financial Times. Though no final decision on the size of asset to be moved is taken yet, Deutsche is likely to trim its balance sheet by about 75%.
BAC HSB 0005 BAC DB HSEA HSEB HSBC HCS HBCYF

 
HBCYF / HSBC Holdings Plc NYSE CERTIFICATION FILING - HSBC HOLDINGS PLC

2018-09-13 sec.gov
begin 644 HSBC8A091318.pdf M)5!$1BTQ+C,*)79E
HBCYF

24
Saudi Arabia wealth fund prepares to sign US$11bil loan

2018-09-12 thestar.com.my
DUBAI: Saudi Arabia’s sovereign wealth fund will sign an US$11bil loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

 
HBCYF / HSBC Holdings Plc 8-A12B

2018-09-12 sec.gov
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HBCYF

24
Saudi wealth fund said to prepare to sign US$11 bil loan

2018-09-12 theedgemarkets
(Sept 12): Saudi Arabia’s sovereign wealth fund will sign an US$11 billion loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: G4634U169